BALAXI — Balaxi Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- IN₹6.30bn
- IN₹6.22bn
- IN₹3.36bn
- 39
- 18
- 63
- 30
Annual income statement for Balaxi Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 136 | 456 | 2,313 | 2,794 | 3,364 |
| Cost of Revenue | |||||
| Gross Profit | 31.3 | 121 | 592 | 838 | 1,337 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 120 | 396 | 1,892 | 2,297 | 2,816 |
| Operating Profit | 16.3 | 60.6 | 421 | 497 | 548 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 24.4 | 88.7 | 443 | 545 | 569 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 19.7 | 61 | 381 | 477 | 460 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 19.7 | 61 | 381 | 477 | 460 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 19.7 | 61 | 381 | 477 | 460 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 6.47 | 6.1 | 38.1 | 47.7 | 45.4 |
| Dividends per Share |